drugset
drugset / Trial / NCT06530966

Phase I Study of ICP-332 in Healthy Subjects

NCT06530966 ↗

Phase 1 Completed 24 enrolled InnoCare Pharma Inc.
RandomizedParallel-groupTriple-blindOther

Summary

A multiple ascending dose phase I study of ICP-332 in healthy subjects

Timeline

Start
2024-07-23
Primary completion
2024-11-08
Completion
2024-11-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ICP-332 Unknown — Oral

Indications

No indication recorded.